Biotechnology Analysts Duncan, Stavropoulos and Kluska, along with Dr. Orchard, Professor-Pediatrics Dept at the University of Minnesota Medical School, discuss current and investigational treatments for Lysosomal Storage Disorders, including Denali Therapeutics’ (DNLI) enzyme transport vehicle (ETV) technology, including recent findings for DNL310, on an Analyst/Industry conference call to be held on February 3 at 12 pm. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on DNLI:
- Cantor Fitzgerald biotech analysts to hold analyst/industry conference call
- Denali Therapeutics initiated with an Outperform at SVB Securities
- Denali Therapeutics announces achievement of RIPK1 milestone for Phase 2 trial
- Centogene, Denali extend observational study on Parkinson’s disease genetics
- Denali Therapeutics announces 2023 milestones